The term "cancer cell reprogramming" is used to define any kind of intervention aimed at transforming cancer cells into terminally differentiated cells. Using this approach, new technologies have been applied with different methods for a more systemic approach to cancer treatment. This review reports on advances of these technologies, including our personal contributions, mainly carried out on endocrine-related cancers. Some of the interventions, aimed at reverting cancer cells into a normal phenotype, are based on the evidence that tumor development is suppressed by the embryonic microenvironment. On the basis of this rationale, experiments have been conducted using stem cell differentiation stage factors (SCDSFs) taken at different stages of development of Zebrafish embryos, oocyte extracts, or naïve human umbilical cord matrix derived stem cells (UMDSCs). SCDSFs induce significant growth inhibition on different tumor cell lines in vitro, likely because of increases in cell cycle regulatory molecules, such as p53 and pRb. Treatment with these factors activates apoptosis and differentiation related to caspase-3. This is achieved via p73 apoptotic-dependent pathway activation with a concurrent normalization of the E-cadherin and beta-catenin ratio. Extracts from prophase amphibian oocytes could reprogram relevant epigenetic alterations in MCF-7 and HCC1954 breast cancer cell lines, while un-engineered (naïve) human UMDSCs attenuated growth of MDA-231 human breast carcinoma cells. A product prepared for human treatments, containing SCDF at very low doses, yielded favorable results in breast cancer and in intermediate-advanced hepatocellular carcinoma. Other reprogramming interventions used in the models of breast, prostate and ovarian cancer cell lines are described. Finally, current and future perspectives of this novel technology are discussed and a new hallmark of cancer is suggested: the loss of differentiation of cancer cells.
INTRODUCTION
The increasing efforts and financial resources devoted to fight cancer, the most life-threatening disease of our century, have led to major advances achieved by basic research that have substantially improved the comprehension of the mechanisms that sustain cancer. Malignant tissue transformation is a dynamic process that results from the accumulation of multiple genetic and epigenetic alterations that give rise to a complex network of pathological molecular signaling pathways. In this context, modeling of the microenvironment during malignant tissue transformation plays a key bidirectional role and maintains and stimulates tumor growth and metastases. Some recognized hallmarks of cancer include: self-sufficiency in growth signals (autocrine stimulation), insensitivity to anti-growth signals, limitless replicative potential, ability to evade apoptosis, support of angiogenesis, immune evasion, invasion of tissues, ability to give rise to metastasis, etc. Each of these abilities derives from a physiological equilibrium broken by collaborating signaling *Address correspondence to this author at the Scientific Institute of Research and Care Multimedica, Milano Italy; Tel: +39 347 7823894; Fax: +39 02 36511201; E-mail: biava@tiscali.it and a supportive tumor microenvironment. The cancer stem cell theory predicts that a small number of cells in cancer, the cancer stem cells, are resistant to conventional chemoand radiation therapy. Cancer stem cells are also thought to be critical for the maintenance of tumor growth and initiation of metastasis. Chemotherapy and radiation therapy act on the actively proliferating cells of cancer, the cancer transits amplifying cells, whereas the cancer stem cells slowly proliferate and are not affected by chemo-or radiation therapy. Thus chemotherapy and radiation therapy are not able to maintain a prolonged control of cancers. During the last few years, therapies that target specific molecular pathways have been introduced and many "biological" drugs based upon a robust rationale elucidating pathological molecular pathways are now available to clinical oncologists. Promising or even excellent results have been obtained for some types of cancers. However, used alone or in combination with more conventional treatment, such approaches so far have not substantially improved prognosis of most types of advanced cancers. Further approaches taking into account the current overall pathophysiological understanding of the biology of cancer, in particular the nature of cancer stem cells, should be investigated. Reprogramming of cancer stem cells appears to be one new way to fight cancer. The term "reprogramming" is now usually used to define any genetic or epigenetic intervention aimed at inducing differentiation of cancer stem cells into a normal phenotype and/or forcing them to become terminally differentiating cells. The principal interventions used for endocrine-related cancer stem cells reprogramming are shown in (Table 1) . These interventions focus on the role of the embryonic microenvironment in the reprogramming tumor cells.
THE EMBRYONIC MICROENVIRONMENT
The embryonic microenvironment is able to reduce or suppress tumor development when embryonic cell differentiation processes are in progress [1, 2] . The administration of carcinogenic substances during organogenesis causes embryonic malformations, but does not produce malignant tumors. However, when organogenesis is complete, the administration of carcinogenic substances induces malignant tumors in the newborn [3] [4] [5] . These data indicate that carcinogenesis can be controlled by factors present in the embryonic microenvironment during cell differentiation. Many years ago it was demonstrated that the injection of embryonic carcinoma cells into a developing blastocyst was capable of regulating cancer cells with loss of their malignant behavior [6] [7] [8] . This effect is position-dependent: carcinoma cells placed in the perivitelline space did not lose their malignant behavior, while carcinoma cells injected into the blastocele lost their malignancy [9, 10] . The regulatory effect was ascribed to diffusive factors and to the complex networks of substances of the embryonic microenvironment [11, 12] . For some time it was thought that this effect was restricted to embryonic tumors such as teratocarcinomas.
However, other tumors, including leukemia, melanoma, liver and breast cancer have now been shown to revert into a normal phenotype and/or differentiate into normal tissue when implanted in the embryo [13] [14] [15] [16] . In addition, malignant melanoma cells will not grow after implantation into a zebrafish embryo, whereas tumors will grow when the melanoma is injected into an adult zebrafish [17] [18] [19] . Melanoma cells will differentiate into mature nervous system cells when implanted into the extraembryonal membrane of the zebrafish embryo, showing that tumor cells have the ability to differentiate into normal tissue of the embryo organism within which they are inserted [20] . Other fates of malignant tumors implanted in the embryo include death of the cells, arrested growth [21] , as well as commitment to differentiating pathways [22] . Kidney carcinoma nuclei obtained from an adult frog can be reprogrammed, when introduced into an oocyte [23] . A similar effect was obtained in mice in that embryonic cells were able to redirect the early development of nuclei from a medulloblastoma; thus demonstrating epigenetic regulation of tumor nucleus by nuclear transfer into an embryonic microenvironment. The embryonic microenvironment is able to reverse the malignant phenotype: the transplanted tumor nuclei gave origin to post-implantation embryos undergoing tissue differentiation [24] . Growth of leukemia cells may also be inhibited when injected into the placenta of ten-day-old mouse embryos [25] ; with birth and development the mature animals have circulating phenotypically normal leukocytes carrying the leukemia cell markers. These data demonstrate that both the placenta and embryonic elements constitute a morphogenetic field able to induce leukemia cells to differentiate. Other authors obtained similar results with different experiments [26, 27] and concluded [63] [64] [65] Endogenous processing of miRNA mimetics Tumor infiltrating dentritic cell reprogramming Ovarian cancer cells [65] Transfer of chromosome 3p fragments Differentially expressed genes Ovarian cancer cells [66] that embryo-mother cross-talk is very important in determining the arrest of tumor growth, because both maternal (decidua) and embryonic tissues contain substances with anticancer properties, which may co-operate in delaying tumor growth [28] . We consider these promising results as a clue to new perspectives not only in cancer biology comprehension, but also in leading to a different therapeutic strategy. Embryonic cells share fundamental features with tumor cells [29, 30] , among these are : proliferation and expression of embryonic proteins (AFP, or ABC transporters), common molecular signals and pathways (i.e. beta-catenin/TCF/WNT Notch, BMP and Hedgehog signals) [31] [32] [33] , and anerobic metabolisms [34] . In addition, the epithelial-to-mesenchymal transition (EMT) observed in cancer tissue [35] [36] [37] , may also be viewed as a "reactivation" of an embryonic program. We now report results from experiments done in our laboratories based on the concept of "differentiation therapy" outlined above [38] .
TREATMENT OF DIFFERENT HUMAN TUMOR LINES WITH STEM CELL DIFFERENTIATION STAGE FACTORS (SCDSFs) TAKEN FROM ZE-BRAFISH EMBRYO
ZR75.1 breast carcinoma ( and also other tumor cell lines such as A172 glioblastoma multiforme, A375 melanoma, ACHN kidney adenocarcinoma, CaCo 2 colon cancer, and H9 acute lymphoblastic leukemia) were treated in vitro with factors extracted from Zebrafish embryos, composed of proteins (99%) and nucleic acid (1%) [unpublished data], as previously described [39, 40] . These factors were taken from embryos at four different stages of development: a) morula stage, characterized by only merely multiplicative events and therefore made up of totipotent embryonic stem cells, b) middle-blastula-gastrula stage, in which totipotent embryonic stem cells differentiate into pluripotent stem cells, c) 5-somite stage, and d) 20-somite stage, in which important differentiation events have taken place that characterize the intermediate and final embryonic differentiation phases. The growth rate of all the cell lines slowed significantly when treated with factors taken at various stages of differentiation, with the percentage of inhibition ranging from 73% for the glioblastoma cell lines to 26% for the melanoma lines. The growth rate did not slow down and in fact tumor proliferation was slightly stimulated when the various cell lines were treated with factors taken during the morula stage. These data underscore the notion that the cell differentiation stages with networks of factors that are able to re-direct tumor cells towards normal cellular development appear in the early phases of the gastrulation process but are absent in merely multiplicative stages, like the morula [41] .
MOLECULAR EVENTS INHIBITING TUMOR GROWTH
Which molecular events are involved in the mechanisms that inhibit tumor growth? Molecules that play a key role in the regulation process of the cell cycle, such as p53 and pRb, are involved through transcriptional and post-translational processes. Specifically, a block of the G1-S cell cycle phase and transcriptional regulation of the p53 tumor suppressor gene were suggested by a significant increase of the concentration of the p53 protein, as revealed by both cytofluorometry and immunohistochemistry, in the cells of certain tumor lines, such as glioblastoma multiforme and melanoma, after the treatment with differentiation factors [42] . On the other hand, for other tumor lines, such as kidney adenocarcinoma, the reduction of tumor cell growth was due to a posttranslational regulation of the retinoblastoma protein (pRb), a regulation that leads to a modification of the ratio between the phosphorylated and non-phosphorylated forms of the protein in favor of the non-phosphorylated form [43] . The non-phosphorylated form blocks the cell cycle by hindering transcription of the E2F-1 gene. In addition, caspase 3 activation is seen after treatment of colon cancer cells with SCDSFs, mainly by increasing the release of E2F-1, leading to c-Myc over-expression and the activation of a p73 apoptotic-dependent pathway. Moreover, there is a concurrent significant normalization effect on the ratio of e-cadherin and beta catenin, with an increase in e-cadherin levels [44] . Finally, there is an almost complete growth-inhibition of cell proliferation of the CaCo2 colon cancer cell line treated concurrently with SCDSFs and 5 Fluorouracil (Fu). In fact, SCDSFs alone produce a significant apoptotic effect, and 5-FU leads to an enhanced additive apoptotic rate at both 24 and 72 hrs. SCDSFs alone, and in association with 5-Fu, trigger both the extrinsic and the intrinsic apoptotic pathways, activating caspases -8, -3 and -7. SCDSFs and 5-Fu alone exerted opposite effects on Bax and Bcl-xL proteins, meanwhile SCDSFs + 5-Fu induced an almost complete suppression of Bcl-xL release and a dramatic increase in the Bax/Bcl-xL ratio [45] . These data suggest that zebrafish embryo factors could improve chemotherapy efficacy with 5 Fluorouracil by reducing the anti-apoptotic proteins involved in drug-resistance processes. Thus, these molecular mechanisms underlying the delay of tumor growth as a result of the treatment with SCDSFs are the basis of understanding how it is possible to induce differentiation or apoptosis. Our experiments indicate that each kind of tumor responds differently to SCDSFs. In future it may be possible to choose different kinds of more specific differentiation factors which could enable more effective reprogramming and differentiation of various tumor stem cells.
IN VIVO
The effects of SCDSFs on tumor growth were tested in vivo after subcutaneous (s.c.) injection of primary Lewis Lung Carcinoma cells into C57BL/6 female syngeneic mice weighing 18-20 gr. A single cell suspension of tumor cells was prepared by mechanical dissociation of tumor mass: 50 microliters (μ) of Dulbecco phosphate buffered saline (DPBS) containing 10 6 viable tumor cells were mixed with our SCDSF and used in the treated animals, while the control group received 50 μl of DPBS alone. The size of the primary tumor was measured with calipers at different days after the injection and the survival time was recorded. A highly significant difference was noted (P<0.001) between treated and control mice both in terms of primary tumor development ( Fig. 1) and of the survival rate in favor of the treated mice [28] .
In a preliminary case report on 200 patients, including 60 with breast cancer in advanced stages, 1 ml of a solution containing SCDF at a very low concentration (3 micrograms/ml) was administered sublingually 3 times daily to the patients. This clinical study was conducted only to evaluate possible adverse effects during the treatment with SCDSF and for this reason a control group was considered not necessary. After 3 years of treatment, in all the 200 patients no adverse effects were recorded. On the contrary 80% of the 200 patients evidenced an improvement of the performance status, evaluated with E.C.O.G scale: generally the performance status shifted from 4 or 3 status to 2 or 1 status. In 60 cases of breast cancer it was recorded, in addition to 80% of improvement in performance status, 4 cases of partial regression and 70% of survival after 3 years [46] . The efficacy of SCDSFs was confirmed in a randomized clinical trial on 179 patients with intermediate to advanced hepatocellular carcinoma. A significant statistical difference between treated and control group was observed (P=0.03) in favor of the treated group with 19.8% regression (2.5% of complete regression), 16% stable disease [47] .
OOCYTE EXTRACTS
Epigenetic alterations may contribute to the initial stages of some cancers [48] . In breast cancer, these include modifications of chromatin organization such as DNA methylation, histone changes and expression of non-coding RNAs. These epigenetic alterations account for abnormal regulation of genes involved in the cell cycle, DNA repair, apoptosis, cell adhesion and signaling, leading to malignant tissue transformation, tumor growth and drug resistance [49] . Silencing of CDKN2A (p161NK4A) HOXA and PCDH gene clusters by DNA methylation and over-expression of Polycomb proteins BMI-1, EZH2 and SUZ12 have been found in spontaneous or induced transformed human mammary epithelial cells [50, 51] . In addition, methylation of some homeobox genes occurs in ductal carcinoma in situ and in the early stage of breast tumors [52] . Fortunately, epigenetic chromatin modifications are reversible and the involved cells can be reprogrammed to obtain reversal or attenuation of the malignant phenotype. For example, extracts taken from prophase amphibian oocytes of axolotl (AOE) and xenopus (XOE) are able to reprogram epigenetic cellular alterations, and epigenetically silenced tumor suppressor genes were reprogrammed to a transcriptionally active state by the chromatin remodeling activities present in amphibian oocyte extracts [53] . Some tumor suppressor genes such as RARB, CST6, CCND2, GAS2 and CDKN2A are silenced or expressed at very low levels in MCF-7 and HCC 1954 cell lines representing luminal and basal breast cancer phenotypes, respectively. Extracts of AOE and XOE prophase oocytes induced re-expression of such genes in both breast cancer cell lines. However, the reprogramming activity of AOE was greater than that of XOE for all genes but CDKN2A and not all the reprogrammed tumor suppressor genes were re-expressed at levels similar to those of normal human mammary epithelial cells.
NAÏVE HUMAN UMBILICAL CORD MATRIX DE-RIVED STEM CELLS
Use of embryonic stem cells and stem cells derived from fetal tissues brings up important ethical problems which complicate their adaptation into the clinical use. Human umbilical cord matrix stem cells (hUCMSCs) are unique stem cells derived from Warton's jelly (termed Warton's jelly stromal cells) which have some stem cell properties that make them of interest for therapy. They can be obtained in large numbers, are negative for CD34 and CD45, grow rapidly, can be frozen/thawed, can be clonally expanded and can easily be engineered to express exogenous proteins [54] . Metastatic growth of MDA-231 human breast carcinoma cells was attenuated in culture and in a mouse xenograft experimental model by un-engineered (naïve) human umbilical cord matrix stem cells (hUCMSC) [55] . In vitro, culture of hUCMSC with MDA-231 carcinoma cells inhibited DNA synthesis, increased the G2 cell population and inhibited colony growth of the carcinoma cells. The inhibited growth of cancer cells is likely to be due to blocking of ERK-1/2 and PI3K/Akt signaling with activation of intrinsic apoptosis signals. The cultured cells homed to tumor tissue in vivo. Rat umbilical cord stem cells completely abolished rat mammary carcinomas with no evidence of metastases or recurrence 100 days post-tumor cell inoculation [56] . The authors concluded that naïve hUCMSCs may be used as cytotherapy for breast cancer. Rat umbilical cord matrix stem cells have unique tumoricidal genes (ADRP-adipocyte differentiation-related protein, Sulf-1-sulfatase 1 and GPI-glucose phosphatase isomerase) that act as tumor suppressor genes [57] .
REPROGRAMMING TELOMERASE AND MAT-8 GENE IN PROSTATE CANCER
A subpopulation of cancer stem-like cells in prostate tumor cell lines and primary prostate cancer tissues that are highly tumorigenic expresses some essential stem cell associated transcription factors (Oct3/4, Sox2, Nanog, Klf4 and c-myc) [58] . Due to their importance in prostate cancer growth, these cancer stem cells seem a likely target for novel strategies for prostate cancer therapy. One of these novel strategies is related to the enzyme telomerase. Telomerase maintains proliferation by lengthening and protectively "capping" telomeres, the tandem repetitive DNA sequences at the ends of human chromosomes. It consists of two components: a reverse transcriptase protein (TERT) and telomerase RNA (Ter). Ter contains a short template sequence used by TERT to synthesize telomeric DNA. Malignant cells from many cancers have significant telomerase expression and activity levels that correlate directly with malignant metastatic potential. New gene constructs to reprogram telomerase have been engineered and validated: 1) small interfering RNA against wild type mouse telomerase RNA ( -MTer-siRNA); 2) mutant-template mouse telomerase RNA (MT-mTer) which encodes incorrect mouse telomeric repeats. Lentiviral delivery of -mTer-siRNA to mouse prostate cancer cells caused suppression of expression of wild type mTer (80% depletion) and concurrent over-expression of MT-mTer (50-fold) [59] . Growth inhibition and rapid apoptosis were induced in cancer progenitor cells isolated from freshly isolated human prostatectomy specimens treated with telomerase interference [60] . Since more than 90% of human cancers up-regulate telomerase activity by TERT expression, it is expected that telomerase interference would significantly affect tumor survival in a wide spectrum of malignancies, thus rendering them susceptible to targeting with MT-Ter/siRNA [61] . Transfection of human PC-3 and LNCaP prostate carcinoma cells with small interfering double-stranded RNA (siRNA) oligonucleotides against the MAT-8 gene produced a specific down-regulation of MAT-8 expression and a significant decrease in cellular proliferation of both cancer cell lines [62] .
ARTIFICIAL TRANSCRIPTION FACTORS (ATFs) IN BREAST CANCER CELLS
Epigenetic reprogramming of breast cancer cells may be accomplished by targeted DNA methylation [63] . Sitespecific DNA methylation and prolonged stable repression of the tumor suppressor Maspin and the oncogene Sox2 can be obtained in breast cancer cells by Zinc-finger ATFs targeting DNA methyltransferase-3a to the promoters of these genes. This approach down-regulates Maspin and Sox2 for longer periods and more effectively than a transient knock-down. Use of multimodular Zinc-finger proteins, linked to epigenetic editing domains, is a novel technique to "selectively and heritably alter gene expression patterns to stably reprogram cell fate" [63] . The zinc finger-based artificial approach selectively suppresses SOX2 gene expression in breast cancer cells and causes decreased tumor cell proliferation and colony formation [64] .
STIMULATION OF PROTECTIVE IMMUNITY AGAINST CANCER BY REPROGRAMMING TU-MOR-ASSOCIATED DENDRITIC CELLS IN VIVO USING mRNA MIMETICS
The endocytic activity and immune activation of ovarian cancer-associated dendritic cells (DC) may be selectively increased by treatment with the immunostimulatory miRNA miR-155. Nanoparticles carrying oligonucleotide duplexes mimicking the bulged structure of endogenous pre-miRNA strongly enhanced miR-155 activity without saturating the RNA-induced silencing complex. Endogenous processing of synthetic miR-155 produced genome-wide transcriptional changes which in turn silenced multiple immunosuppressive mediators. Tumor infiltrating DCs were transformed from immunosuppressive to highly immunostimulatory cells, activating strong antitumor responses that impeded the progression of established ovarian cancer. This result demonstrates the therapeutic potential of supplementing non viral mRNA mimetics in vivo to strongly increase protective immunity against lethal tumors [65] .
REPROGRAMMING OF THE TRANSCRIPTOME IN A NOVEL EPITHELIAL OVARIAN CANCER CELL LINE MODEL
Transfer of chromosome 3p fragments in a novel epithelial ovarian cancer cell line model (OV-90) lacking 3p will induce tumor suppression. Tumor suppression is associated with a modified transcriptome by microarray analysis. To define the relevance of the altered transcriptome, the differentially expressed genes were studied by Affymetrix analysis in the 3p transfer studies and were integrated with a comparative microarray analysis of normal ovarian surface epithelial cells and malignant ovarian cancers. Reprogramming of the transcriptome appeared to occur as a consequence of the chromosome 3 transfer and tumor suppression affected molecular networks sustaining ovarian carcinogenesis [66] .
DISCUSSION

Induction of Cancer is a Microevolutive Process Based on Many Complex Modifications As a Result of Genetic and Epigenetic Events in Cells Interactive with Microenvironmental Signals
The demonstration of effective use of SCDSFs in antitumor treatment supports the concept that cancers are maintained by stem-like cells which can be induced to differentiate through signals provided by the embryonic microenvironment [1] . The new reprogramming treatments herein described were conceived to address the chemoresistance of cancer stem-like cells. We propose that the initial process of carcinogenesis could be either 1) a mutation that may slightly or severely alter DNA or 2) an epigenetic modification which can affect the DNA stability, thus leading to an increased risk of genomic changes. The higher structural order of chromatin, which governs the replication timing and nuclear architecture, is determined, at least partly, by epigenetic states of genomic regions which in turn can affect the expression patterns of the genome of cancer cells. DNA methylation and histone modifications play a crucial role in gene regulation and an aberrant epigenome can introduce genomic alterations via multiple mechanisms [67] . The transformation of a normal cell into a cancer cell is believed to be a process involving a minimal number of stochastic mutational events, between four and seven. If, however, mutations are introduced into normal cells in a non stochastic manner, i.e. triggering at precise genes, this number is reduced [68] . The preferred targets of these mutations are genes encoding for key effectors of cell cycle regulation and cell signaling, and for growth factors and their receptors. Mutations are either gain-of-function, in the case of protooncogenes, or loss-function, in the case of tumor suppressor genes. For normal cells to become cancerous, transformation also depends on a complex network of surrounding microenvironmental signals from cell-to-cell "cross-talk", from soluble extracellular factors or from extracellular matrix. For example, tumor progression may be mediated by fibroblasts adjacent to prostate epithelium carcinoma [69] and malignant transformation of immortalized keratinocytes may be enhanced by release of proliferative stimuli from neighboring cells in the stroma [70] , including inflammatory cells [71] . Even pro-inflammatory cytokines may promote cancer cell proliferation by inhibiting tumor suppression pathways [72] . Thus both the cancer cells and the tissue context are decisive in determining cell fate in line with a " heterotypic" view of cell biology, as it was called in a review [73] . According to this view, cancer could be defined as a microevolutive process. A cancer cell acquires, as a consequence of this process, the biologic behavior that we identify with cancer: 1) selfsufficiency in growth signals, 2) insensitivity to antigrowth signals, 3) limitless replicative potential, 4) ability to evade apoptosis, 5) induction of angiogenesis, 6) invasion of tissue and 7) metastasis. Nonetheless the model of cancer described [1] assumes that regardless of how the steps in these genetic pathways are arranged, the development of all types of tumors is governed by a final common process. In fact the research carried out in our labs has suggested that a great variability of the processes used by cells to become malignant is stabilized by what the chaos theory refers to as "attractor", that leads the genome of tumor cells to a new configuration.
Cancer Cells and Stem Cells
Depending on the degree of malignancy, the lineage of tumor cells is similar to that present at different stages of normal development and differentiation [38] . Tumor cells are arrested at various stages at differentiation where proliferation is active, i.e. prior to terminal differentiation. This "maturation arrest" may be the result of genetic and/or epigenetic alterations. We consider the epigenetic changes, linked to the new gene configurations, very similar to those present in stem cells. This process describes the mechanisms whereby a normal tissue cell becomes blocked during maturation and does not further differentiate. This model of cancer is supported by our experiments which show that the factors that differentiate stem cells are capable of inducing differentiation of tumor cells or causing apoptosis, bypassing the mutations that are the source of the malignancy.
In keeping with this approach, we recall the characteristics shared by both tumor and normal stem cells: tumor cells have oncofetal antigens, which are maintained during phylogenesis [74] , and specific receptors on the cell membrane on which stem cell differentiation factors likely act. In addition, tumor and stem cells share common signals and pathways such as the APC/beta catenin/TCF/Wnt and Hedgehog/Smoothened/Patched pathways [31, 32] . The problem with tumor cells is twofold: not only do they harbor genetic mutations, which are usually at the origin of the malignancy, but they also have significant epigenetic modifications. The genetic configuration and the metabolism of tumor cells are very similar to those of normal stem cells in that both have active proto-oncogenes, both produce embryonic growth factors, both, as already mentioned, have oncofetal antigens, and both function with an anerobic metabolism. The difference between stem cells and tumor cells lies in the fact that the latter, because of the genetic and epigenetic alteration, are no longer able to complete development and to differentiate. In addition, the chemoresistant cells of tumors are the cancer stem cells [75] . Cancer stem cells have been identified in many types of solid tumors, such as glioblastoma multiforme [76] [77] [78] , breast cancer [79] [80] [81] [82] [83] [84] , lung cancer [85] [86] [87] [88] , prostate cancer [89] [90] [91] , ovarian cancer [92] [93] [94] [95] [96] liver cancer [97] [98] [99] [100] [101] [102] [103] , gastric cancer [104] [105] [106] [107] [108] , colon cancer [109] [110] [111] , pancreas cancer [112] [113] [114] , and squamous carcinoma of the head and neck [115] [116] [117] [118] . Moreover, the presence of cancer stem cells is characteristic of many hematological malignant diseases.
The studies recorded in this review agree with an extensive series of research regarding the theories on attractors as morphogenetic fields. More than 50 years ago, some authors [119, 120] speculated that cancer could be represented as an escape from morphogenetic fields like those which guide the embryonic development. Any change that leads a stem cell to escape from its own niche would result in tumor formation [121] . On the other hand, malignant tumor cells placed into a morphogenetic field, like that of an embryo, can be reprogrammed into expressing a non-malignant phenotype [122, 123] . Cancer can be considered an emergent property of living tissues under an attractor-destabilizing, chronic stimulation, involving not only DNA or single-somatic cell functions, but also system features [124] . If genomic alterations move to a cancer transcriptome, considered as "a whole", a more interesting picture emerges, from which it is possible to observe a very great degree of order [125] . Indeed, cluster analysis of tumor transcriptomes classifies tumors into a small number of discretely distinct groups, organizing the transcriptomes of cell types into groups of related tissues [126] . This clustering classification agrees well with the traditional classification of tumors derived from morphology and from a vision of cancer that considers its ontological origin [1] . In this review, we have focused on endocrine cancers, but as a systemic approach to cancer treatment, many other experiments in various non endocrine-related tumors are in progress using a similar approach [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] .
CONCLUSIONS
Understanding the mechanisms of cell differentiation and the various metabolic pathways that are common to cancer and stem cells is providing new insights into the treatment of cancer. The most important approach involves reprogramming cancer cells to undergo terminal differentiation. The application of this approach in the treatment of endocrine-related cancer is the topic of this review. Our proposed model of cancer [1] takes into consideration that the reprogramming treatments are complex. In fact, cell differentiation mechanisms consist of a multigenic regulation; a more differentiated cell differs from a less differentiated one because of the expression of a great number of genes. Therefore, if the ultimate goal is not to destroy cancer cell, but to differentiate and reprogram it [141, 142] , this goal can clearly be achieved only by providing the cell with all the required reprogramming factors. These factors can be found during organogenesis. When new tissues are being formed there is the whole repertoire of regulatory molecules, including the transcriptional, post-transcriptional, translational, post-translational regulators, required to differentiate stem cells. Cancer stem cells can be induced to revert to a normal phenotype only when the network of differentiation factors is specific and complete enough for controlling that kind of cells. SCDFs represent specific differentiation factors able to activate p53 oncosupressor gene or to regulate in posttranslational manner pRb protein. SCDFs are able to arrest cell cycle of tumor cells, because, as demonstrated recently by other authors [143] , p53 is responsible for transactivation of several miRNAs and RBPs. Members of the p53 network, including miRNAs and RBPs, work coordinately with proteincoding p53 targets during tumor suppression. p53-induced miR34 opposes oncogenic phenotypes and miR34 limits cell division, by targeting mRNAs of several members of RTK/RAS/RAF/MAPK cascades. miRNA-34a also targets SNAIL, while the miR-200 family and miR-205 target ZEB1/2 to prevent EMT. In addition p53 generates multiple pro-apoptotic signals, including miR-34a-dependent repression of BCL2, leading to mitochondrial outer membrane permeabilization, downstream caspase activation and ultimately, apoptosis. On the other hand SCDFs cause, as we have demonstrated in kidney adenocarcinoma, a slowdown of tumor cell growth, through a post-translational regulation of the retinoblastoma protein (pRb), a regulation that leads to a modification of the ratio between the phosphorylated and nonphosphorylated form of the protein in favor of the non-phosphorylated form [43] . The non-phosphorylated form blocks the cell cycle by hindering transcription of the E2F-1 gene. In future, the identification of any new molecular pathway of cancer will help in solving the puzzle. Reprogramming treatments can be effective, even if they reprogram a single step in a specific metabolic pathway such as the ability of imatinib mesylate to reverse the constitutive activation of myelocytes in chronic myelocyte leukemia [144] , or the function of specific molecules, which play an important role in cell survival, such as telomerase, in the treatment of prostate cancer. In any case, similar treatment approaches directed toward inducing differentiation of cancer stem cells require a more complex and integrated comprehension of the biological processes that sustain maturation arrest of cancer cells and this leads us to suggest a new hallmark of cancer in addition to the others [145] : the loss of differentiation of cancer cells.
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